⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
Form 8-K
sec.gov
OSTX
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
businesswire.com
OSTX
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
businesswire.com
OSTX
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor Ready to Announce with Confidence?
newsfilecorp.com
OSTX
GENK
PFE
Form 8-K
sec.gov
OSTX
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors Ready to Announce with Confidence?
newsfilecorp.com
OSTX